United States Rep. Timothy Waltz (D-MN), along with over 30 bipartisan co-sponsors, has introduced legislation, HR 5520: The VA Medicinal Cannabis Research Act of 2018, to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans.
The legislation states: “In carrying out the responsibilities of the Secretary of Veterans Affairs, … the Secretary may conduct and support research relating to the efficacy and safety of forms of cannabis … on the health outcomes of covered veterans diagnosed with chronic pain, post-traumatic stress disorder, and other conditions the Secretary determines appropriate.”
According to nationwide survey data compiled by The American Legion, 39 percent of respondents affirmed that they “know a veteran” who is using the plant medicinally. Twenty-two percent of respondents said they themselves “use cannabis to treat a mental or physical condition.” Yet, VA Secretary David Shulkin has consistently rejected calls from veterans groups and lawmakers to study the use of cannabis among military veterans.
Passage of HR 5520 explicitly authorizes “the Secretary to conduct and support research on the efficacy and safety of medicinal cannabis.”
Representative Walz, who is the ranking member of the House VA committee, said: “While we know cannabis can have life-saving effects on veterans suffering from chronic pain or PTSD, there has been a severe lack of research studying the full effect of medicinal cannabis on these veterans. Simply put, there is no department or organization better suited to conduct this critically important research than VA, and there will never be a better time to act.”
Please click here to urge your federal lawmakers to support HR 5520: The VA Medicinal Cannabis Research Act of 2018.